Gabapentin enacarbil
- Generic Name
- Gabapentin enacarbil
- Brand Names
- Horizant
- Drug Type
- Small Molecule
- Chemical Formula
- C16H27NO6
- CAS Number
- 478296-72-9
- Unique Ingredient Identifier
- 75OCL1SPBQ
- Background
Gabapentin enacarbil is marketed under the name Horizant. It is a prodrug of gabapentin, and indicated in adults for the treatment of Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).
- Indication
For the treatment of adult Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).
- Associated Conditions
- Postherpetic Neuralgia, Restless Legs Syndrome (RLS)
- Associated Therapies
- -
Familiarize Yourself With Updated Clinical Guidelines Recommendations for Restless Legs
Restless legs syndrome (RLS) involves an urge to move legs, often worsening at rest, affecting sleep and quality of life. The American Academy of Sleep Medicine (AASM) updated guidelines in 2024 recommend iron supplementation for low ferritin levels, alpha-2-delta ligands like gabapentin for treatment, and non-pharmacological options like high-frequency bilateral peroneal nerve stimulation. The guidelines discourage the use of dopamine agonists and levodopa due to long-term complications, emphasizing safer alternatives.
The risks of dopamine agonists for the treatment of restless legs syndrome
In 2005, ropinirole was approved for RLS, becoming a first-line therapy. By 2024, dopamine agonists like ropinirole are on the 'do not use' list due to augmentation and impulse control disorders. Effective alternatives include iron therapy, gabapentin, opioids, dipyridamole, and a nerve stimulator band.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath